{"id":"https://openalex.org/W2118396147","doi":"https://doi.org/10.1093/intimm/dxu095","title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","display_name":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","publication_year":2014,"publication_date":"2014-10-16","ids":{"openalex":"https://openalex.org/W2118396147","doi":"https://doi.org/10.1093/intimm/dxu095","mag":"2118396147","pmid":"https://pubmed.ncbi.nlm.nih.gov/25323844"},"language":"en","primary_location":{"id":"doi:10.1093/intimm/dxu095","doi":"https://doi.org/10.1093/intimm/dxu095","is_oa":false,"landing_page_url":"https://doi.org/10.1093/intimm/dxu095","pdf_url":null,"source":{"id":"https://openalex.org/S5544371","display_name":"International Immunology","issn_l":"0953-8178","issn":["0953-8178","1460-2377"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Immunology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2118396147"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110813813","display_name":"George K. Philips","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799903593","display_name":"Georgetown University Medical Center","ror":"https://ror.org/00hjz7x27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799903593"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"George K. Philips","raw_affiliation_strings":["Department of Medicine, Georgetown University Hospital 1 , 3800 Reservoir Road NW, Washington DC 20007 , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Georgetown University Hospital 1 , 3800 Reservoir Road NW, Washington DC 20007 , USA","institution_ids":["https://openalex.org/I2799903593"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5052526230","display_name":"Michael B. Atkins","orcid":"https://orcid.org/0000-0003-3901-9924","observed_orcids":["https://orcid.org/0000-0003-3901-9924"]},"institutions":[{"id":"https://openalex.org/I4390039356","display_name":"Georgetown Lombardi Comprehensive Cancer Center","ror":"https://ror.org/035zrb927","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I184565670","https://openalex.org/I4390039356"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Atkins","raw_affiliation_strings":["Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center 2 , Research Building-E501, 3970 Reservoir Road NW, Washington DC 20057, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Georgetown-Lombardi Comprehensive Cancer Center 2 , Research Building-E501, 3970 Reservoir Road NW, Washington DC 20057, USA","institution_ids":["https://openalex.org/I4390039356"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3530,"currency":"USD","value_usd":3530},"apc_paid":null,"fwci":4.9602,"has_fulltext":true,"cited_by_count":344,"citation_normalized_percentile":{"value":0.97965335,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":99,"max":100},"biblio":{"volume":"27","issue":"1","first_page":"39","last_page":"46"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-pd-1-antibody","display_name":"anti-PD-1","score":0.9769999980926514},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":1.0},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.8820000290870667},{"id":"https://openalex.org/keywords/immune-checkpoint","display_name":"immune checkpoint","score":0.9390000104904175},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9570000171661377},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":0.9900000095367432},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7170000076293945},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.8880000114440918},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.8220000267028809},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.703000009059906},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8820000290870667},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.8109999895095825},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.7480000257492065}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.7578665018081665},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6888006925582886},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6655504703521729},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.563827633857727},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5298835039138794},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5235709547996521},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5154581665992737},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.47534891963005066},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.44638746976852417},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.44103696942329407},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4122341275215149},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36027956008911133},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.235763818025589}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007111","descriptor_name":"Immunity, Cellular","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D060890","descriptor_name":"B7-H1 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1093/intimm/dxu095","doi":"https://doi.org/10.1093/intimm/dxu095","is_oa":false,"landing_page_url":"https://doi.org/10.1093/intimm/dxu095","pdf_url":null,"source":{"id":"https://openalex.org/S5544371","display_name":"International Immunology","issn_l":"0953-8178","issn":["0953-8178","1460-2377"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Immunology","raw_type":"journal-article"},{"id":"pmid:25323844","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25323844","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International immunology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W289544031","https://openalex.org/W1538902372","https://openalex.org/W1829526068","https://openalex.org/W1904205116","https://openalex.org/W1996145004","https://openalex.org/W2001287101","https://openalex.org/W2004630197","https://openalex.org/W2010121426","https://openalex.org/W2016789384","https://openalex.org/W2021588881","https://openalex.org/W2052874737","https://openalex.org/W2057893793","https://openalex.org/W2097995306","https://openalex.org/W2101653483","https://openalex.org/W2105396178","https://openalex.org/W2107408397","https://openalex.org/W2107484016","https://openalex.org/W2108933323","https://openalex.org/W2117692326","https://openalex.org/W2118982164","https://openalex.org/W2121770645","https://openalex.org/W2127735232","https://openalex.org/W2129806226","https://openalex.org/W2143163879","https://openalex.org/W2144547008","https://openalex.org/W2155464214","https://openalex.org/W2160834915","https://openalex.org/W2163804741","https://openalex.org/W2249078564","https://openalex.org/W2311550469","https://openalex.org/W2473280483","https://openalex.org/W2476006635","https://openalex.org/W2499376400","https://openalex.org/W2513578542","https://openalex.org/W2526642223","https://openalex.org/W2580751003","https://openalex.org/W2600223557","https://openalex.org/W2672265346","https://openalex.org/W2791808262","https://openalex.org/W3011071920","https://openalex.org/W4230861071","https://openalex.org/W4244304327"],"related_works":["https://openalex.org/W2104231624","https://openalex.org/W2075027825","https://openalex.org/W2952065098","https://openalex.org/W1984246609","https://openalex.org/W1979560263","https://openalex.org/W2096322385","https://openalex.org/W1997104993","https://openalex.org/W2794612508","https://openalex.org/W4232338358","https://openalex.org/W2995312529"],"abstract_inverted_index":{"Despite":[0],"extensive":[1],"investigation":[2],"over":[3],"the":[4,20,27,55,105,115],"past":[5],"three":[6],"decades,":[7],"cancer":[8,219],"immunotherapy":[9],"has":[10],"produced":[11,146],"limited":[12],"success,":[13],"with":[14,37,127,133,150,159,168],"few":[15],"agents":[16,234],"achieving":[17],"approval":[18],"by":[19],"Food":[21],"and":[22,25,76,86,161,172,174,191,218,235,240,243],"Drug":[23],"Administration":[24],"even":[26],"most":[28],"effective":[29],"helping":[30],"only":[31],"a":[32],"minority":[33],"of":[34,57,188,195,232,247],"patients,":[35],"primarily":[36],"melanoma":[38,160],"or":[39,143],"renal":[40,162],"cancer.":[41],"In":[42],"recent":[43],"years,":[44],"immune":[45,112],"checkpoints":[46],"that":[47],"maintain":[48],"physiologic":[49],"self-tolerance":[50],"have":[51,66,145,197],"been":[52],"implicated":[53],"in":[54,114,125,157,237],"down-regulation":[56],"anti-tumor":[58,64,148],"immunity.":[59],"Efforts":[60],"to":[61,100,181,184],"restore":[62,101,111],"latent":[63],"immunity":[65,103],"focused":[67],"on":[68,83,91,229],"antibody-based":[69],"interventions":[70],"targeting":[71,97,140],"CTL":[72],"antigen":[73],"4":[74],"(CTLA-4)":[75],"programmed":[77],"cell":[78],"death":[79],"protein":[80],"1":[81],"(PD-1)":[82],"T":[84],"lymphocytes":[85],"its":[87],"principal":[88],"ligand":[89],"(PD-L1)":[90],"tumor":[92,102,116],"cells.":[93],"Ipilimumab,":[94],"an":[95],"antibody":[96],"CTLA-4,":[98],"appears":[99],"at":[104],"priming":[106],"phase,":[107],"whereas":[108],"anti-PD-1/PD-L1":[109],"antibodies":[110,139],"function":[113],"microenvironment.":[117],"Although":[118],"ipilimumab":[119],"can":[120],"produce":[121],"durable":[122],"long-term":[123],"responses":[124],"patients":[126,158],"advanced":[128],"melanoma,":[129],"it":[130],"is":[131],"associated":[132],"significant":[134,147],"immune-related":[135],"toxicities.":[136],"By":[137],"contrast,":[138],"either":[141],"PD-1":[142],"PD-L1":[144],"activity":[149],"considerably":[151],"less":[152],"toxicity.":[153],"Activity":[154],"was":[155],"seen":[156],"cancer,":[163],"as":[164,166],"well":[165],"those":[167],"non-small-cell":[169],"lung,":[170],"bladder":[171],"head":[173],"neck":[175],"cancers,":[176],"tumors":[177],"not":[178],"previously":[179],"felt":[180],"be":[182],"sensitive":[183],"immunotherapy.":[185],"The":[186],"tolerability":[187],"PD-1-pathway":[189],"blockers":[190],"their":[192],"unique":[193],"mechanism":[194],"action":[196],"made":[198],"them":[199],"ideal":[200],"backbones":[201],"for":[202],"combination":[203],"regimen":[204],"development.":[205],"Combination":[206],"approaches":[207],"involving":[208],"cytotoxic":[209],"chemotherapy,":[210],"anti-angiogenic":[211],"agents,":[212],"alternative":[213],"immune-checkpoint":[214],"inhibitors,":[215],"immunostimulatory":[216],"cytokines":[217],"vaccines":[220],"are":[221],"currently":[222],"under":[223],"clinical":[224],"investigation.":[225],"Current":[226],"efforts":[227],"focus":[228],"registration":[230],"trials":[231],"single":[233],"combinations":[236],"various":[238],"diseases":[239],"disease":[241],"settings":[242],"identifying":[244],"predictive":[245],"biomarkers":[246],"response.":[248]},"counts_by_year":[{"year":2026,"cited_by_count":8},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":14},{"year":2023,"cited_by_count":27},{"year":2022,"cited_by_count":21},{"year":2021,"cited_by_count":32},{"year":2020,"cited_by_count":36},{"year":2019,"cited_by_count":34},{"year":2018,"cited_by_count":39},{"year":2017,"cited_by_count":43},{"year":2016,"cited_by_count":52},{"year":2015,"cited_by_count":23}],"updated_date":"2026-11-15T12:55:33.944570","created_date":"2016-06-24T00:00:00"}